Latest news with #GENETICS
Cision Canada
7 days ago
- Business
- Cision Canada
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
, Aug. 5, 2025 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an expansion of its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN). This new, multi-year collaboration will leverage SOPHiA GENETICS's multimodal AI Factories to generate evidence on the efficacy, value, and real-world impact of therapies for certain types of breast cancer. It will also support the potential development of a bespoke AI-powered predictive model aimed at optimizing outcomes for individuals undergoing treatment for breast cancer. Derived from cutting-edge computing protocols and trained on one of the most diverse multimodal datasets in healthcare, SOPHiA GENETICS's AI Factories offer powerful predictive insights for assessing patient prognosis and treatment response. AstraZeneca will utilize SOPHiA GENETICS's AI Factories to analyze multimodal healthcare data — including genomics, imaging, and clinical data — and generate AI-powered insights to help optimize breast cancer outcomes. The companies will also collaborate on real-world evidence generation in Europe and North America to uncover key drivers of treatment efficacy, address critical knowledge gaps, and enhance clinical decision-making through deeper insights. "We are proud to deepen our partnership with AstraZeneca through this significant new initiative, which highlights the growing demand for secure, compliant, and scalable real-world AI applications," said Ross Muken, President of SOPHiA GENETICS. "Our platform is purpose-built to manage complex healthcare data environments, and this collaboration reinforces our shared commitment to driving better patient outcomes through trusted, federated analytics powered by data and AI." "At AstraZeneca, a core component of our AI strategy has been rooted in the deployment of frontier AI solutions across oncology clinical development," said Jorge Reis-Filho, Chief AI and Data Scientist, AstraZeneca. "Fine tuning and augmenting our models with multimodal data – including our own data and the data that will be generated as part of this collaboration – is helping us to generate a more holistic understanding of disease biology and biomarkers to tailor the most effective treatment to patients living with cancer." This collaboration reinforces SOPHiA GENETICS' position as a trusted technology partner and underlines its commitment to advancing global health through federated data analytics and artificial intelligence. For more information on SOPHiA GENETICS, visit or connect on LinkedIn. About SOPHiA GENETICS SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit and connect with us on LinkedIn. SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence. SOPHiA GENETICS Forward-Looking Statements: This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Business Wire
18-06-2025
- Science
- Business Wire
Objective Biotechnology Launches First-Ever Automated Microinjection Robot for Genetic Research
MINNEAPOLIS--(BUSINESS WIRE)--Objective Biotechnology, a pioneer in next-generation research tools, today announced the commercial launch of the Autoinjector, the first fully automated robotic system for microinjection in genetic research. Developed in collaboration with the University of Minnesota, the system was validated in a GENETICS study showing its speed, accuracy, and broad utility across model organisms. Microinjection is an essential but slow step in genetic research, traditionally requiring technicians to manually align and inject each embryo with precision. The Autoinjector transforms this process by combining computer vision and machine learning, delivering consistent, high-precision injections up to four times faster than manual methods—while reducing training time from months to weeks. The Autoinjector also enables entirely new high-throughput experiments that aren't feasible by hand. In the study published in GENETICS, researchers used it to inject over 20,000 uniquely barcoded DNA plasmids into 1,700 Drosophila embryos in just two days—generating more than 400 unique transgenic lines and, for the first time, allowing scientists to measure how many independent germline integrations occurred per embryo. The study also demonstrated that the Autoinjector significantly improved vitrification rates and post-thaw survival of zebrafish, outperforming traditional manual injection. 'The system has already demonstrated success in gene editing and transgenesis experiments across both insect and vertebrate models at multiple early-access sites,' said James Grabau, CEO of Objective Biotechnology. 'The Autoinjector is designed to remove a stubborn and persistent bottleneck in the process of generating transgenic models in a variety of species and applications.' 'The Autoinjector comes pre-loaded with injection protocols for commonly used model organisms such as Drosophila and zebrafish, and it can be fully customized for emerging or non-model species,' said Daryl Gohl, Chief Scientific Officer of Objective Biotechnology. 'This flexibility makes the Autoinjector particularly valuable for labs working across multiple species, providing them with the ability to streamline both basic and applied genetic research.' Objective Biotechnology is a leader in developing innovative solutions for genetic engineering and neurotechnology. Its mission is to accelerate discovery by equipping scientists with cutting-edge tools that simplify, scale, and expand what's possible in modern genetics and neuroscience.
